ANNEXON BIOSCIENCES
Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. The company’s first product... candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The company’s second product candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. Annexon is advancing its current programs while evaluating additional orphan and large market indications. Annexon is deploying a disciplined, biomarker-driven development strategy designed to establish that its product candidates are engaging the target at a well-tolerated therapeutic dose in the intended patient tissue.
ANNEXON BIOSCIENCES
Social Links:
Industry:
Biotechnology Health Care Health Diagnostics Life Science Therapeutics
Founded:
2011-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.annexonbio.com
Total Employee:
51+
Status:
Active
Contact:
(650)822-5500
Email Addresses:
[email protected]
Total Funding:
634 M USD
Technology used in webpage:
Domain Not Resolving Google Maps CrUX Top 50m Amazon Virginia Region CloudFront COVID-19 Amazon Route 53 Amazon SSL Symantec Secure Site
Similar Organizations
Sagimet Biosciences
Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases.
Ambrx
Ambrx develops protein therapeutics that preserve potency, reduce dosing frequency, and improve homogeneity of the drug substance.
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Kezar Life Sciences
Kezar Life Sciences company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders
Knopp Biosciences
Knopp Neurosciences is a drug discovery and development company working on treatments for neurological disorders.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Salvo Health
Launching specialty health clinics to radically improve member outcomes.
Simple HealthKit
Simple HealthKit provides rapid diagnostic solutions, and wellness tests for universities, employers, clinics, and pharmacies.
Spark Neuro
SPARK Neuro is a neuroscience company that revolutionizes the of audience engagement in advertising and entertainment.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Satter Investment Management
Satter Investment Management investment in Post-IPO Equity - Annexon Biosciences
Fairmount Funds Management
Fairmount Funds Management investment in Post-IPO Equity - Annexon Biosciences
Driehaus Capital Management
Driehaus Capital Management investment in Post-IPO Equity - Annexon Biosciences
Adage Capital Management
Adage Capital Management investment in Post-IPO Equity - Annexon Biosciences
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners investment in Post-IPO Equity - Annexon Biosciences
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Post-IPO Equity - Annexon Biosciences
Redmile Group
Redmile Group investment in Post-IPO Equity - Annexon Biosciences
Satter Investment Management
Satter Investment Management investment in Series C - Annexon Biosciences
New Enterprise Associates
New Enterprise Associates investment in Series C - Annexon Biosciences
Adage Capital Management
Adage Capital Management investment in Series C - Annexon Biosciences
Key Employee Changes
Official Site Inspections
http://www.annexonbio.com Semrush global rank: 2.59 M Semrush visits lastest month: 7 K
- Host name: 41.102.145.34.bc.googleusercontent.com
- IP address: 34.145.102.41
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Annexon Biosciences"
About - Annexon Biosciences
OUR MISSION We’re passionate about bringing game-changing therapies to patients suffering from serious complement-mediated autoimmune, neurodegenerative and ophthalmic disorders OUR History 2007 Dr. Ben …See details»
Annexon Biosciences Expands Leadership Team with the …
“I’m pleased to welcome Michael to our organization as we look to leverage his expertise across the organization, and in particular with regard to our corporate and commercial development …See details»
Annexon Biosciences - Crunchbase Company Profile
Contact Email [email protected] Phone Number (650)822-5500 Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the …See details»
Contact Annexon | Annexon Inc.
[email protected]. Media: Sheryl Seapy Real Chemistry 949-903-4750 [email protected]. Print . IR Contact. RSS Feeds. Email Alerts. Contact Us. …See details»
Annexon Biosciences CEO and Key Executive Team | Craft.co
Annexon Biosciences's President, Chief Executive Officer, Director is Douglas Love. Other executives include Ted Yednock, Executive Vice President, Chief Innovation Officer; Larry C. …See details»
Annexon Biosciences - LinkedIn
Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, …See details»
Working At Annexon: Company Overview and Culture - Zippia
Annexonbio.com. Organization Type. Public. CEO. Douglas Love. Social Media. Annexon Biosciences is the development of therapeutic products that halt the progression of …See details»
Annexon Biosciences - Overview, News & Similar companies
May 16, 2024 Annexon Biosciences to Present at the Bank of America Health Care Conference BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a …See details»
Our Culture - Annexon Biosciences
Our Culture Literally show up as you are — just show up and add value.Our culture is very open and direct, but very respectful.There’s a casual intensity to us where we seek to have fun while …See details»
News Release Details - ir.annexonbio.com
“I’m pleased to welcome Michael to our organization as we look to leverage his expertise across the organization, and in particular with regard to our corporate and commercial development …See details»
Annexon Biosciences to Present at the 42nd Annual J.P. Morgan ...
BRISBANE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based …See details»
Annexon Biosciences - Bain Capital Life Sciences
Annexon Biosciences (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company utilizing a distinct scientific approach to stop C1q and all inflammatory aspects of classical complement …See details»
Annexon Biosciences Strengthens Leadership Team with …
Dr. Dananberg joins Annexon with more than 20 years of drug development experience across a variety of therapeutic areas in the pharmaceutical and biotechnology industries. Most recently, …See details»
Annexon Biosciences Highlights Portfolio Progress and Key …
May 9, 2022 For more information, visit www.annexonbio.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of …See details»
Science - Annexon Biosciences
STOP COMPLEMENT-MEDIATEDDISEASES AT THE START C1q is the initiating molecule of the classical complement pathway that activates a powerful inflammatory cascade. Our …See details»
News Releases - Annexon Inc.
Oct 15, 2024 The Investor Relations website contains information about Annexon Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Pipeline - Annexon Biosciences
STOP COMPLEMENT-MEDIATED DISEASES AT THE START Annexon is pioneering a class of new complement medicines for patients with classical complement-mediated disorders of the …See details»
Annexon Biosciences Provides Business Update and Reports First …
May 17, 2021 For more information, visit www.annexonbio.com. Forward Looking Statements. This press release contains forward-looking statements within the meaning of Section 27A of …See details»
News Release Details - Annexon Inc.
SOUTH SAN FRANCISCO, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Today Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a …See details»